TEMPEST THERAPEUTICS INC (TPST)
US87978U1088 - Common Stock
TEMPEST THERAPEUTICS INC
NASDAQ:TPST (11/22/2024, 4:48:45 PM)
After market: 0.9055 0 (0%)0.9055
+0.01 (+1.33%)
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company is headquartered in Brisbane California, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA
P: 14157988589
CEO: Louis Arcudi
Employees: 17
Website: https://www.tempesttx.com/
TPST News
10 days ago - Tempest TherapeuticsTempest Reports Third Quarter 2024 Financial Results and Provides Business Update10 days ago - Tempest TherapeuticsTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateBuilding upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination...
10 days ago - Tempest TherapeuticsTempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinomaa month ago - Yahoo FinanceWhy Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?Tempest Therapeutics Inc. (NASDAQ:TPST) stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro. The company entered into an agreement with Roche Holdings AG (OTC:RHHBY) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a Phase 3 trial for the first-line treatment of liver cancer.
a month ago - Tempest TherapeuticsTempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal TrialThe company is preparing for the Phase 3 study start in the first quarter of 2025
a month ago - Tempest TherapeuticsTempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal TrialThe company is preparing for the Phase 3 study start in the first quarter of 2025...
TPST Twits
Here you can normally see the latest stock twits on TPST, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
